Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
NCT00327119
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
ABX-EGF (panitumumab)
Sponsor
Amgen